The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values
The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values: Can we Save Some MRI Scans?
Sponsors |
Lead Sponsor: Chinese University of Hong Kong |
---|---|
Source | Chinese University of Hong Kong |
Brief Summary | This study is to investigate, in a larger cohort of consecutive men, the proportion of abnormal MRI prostate in different phi ranges, and the cancer detected in Chinese men with abnormal MRI. This study aims to evaluate whether MRI prostate can be omitted in men with lower suspicion of prostate cancer. |
Detailed Description | This is a prospective cohort study recruiting consecutive men with elevated blood test PSA 4-10 ng/mL, normal prostate on digital rectal examination, and result for blood Prostate Health Index (phi) known. A multi-parametric MRI prostate with contrast will be performed in all subjects. MRI prostate will be reported according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations[10] and scored from 1 to 5. A PI-RADS score of 3-5 is considered abnormal. The proportion of abnormal MRI in different phi ranges (primary outcome) will be compared. The subjects will be offered a prostate biopsy according to usual clinical indications in our hospital: In men with phi >35 (higher risk of significant prostate cancer), prostate biopsy (systematic biopsy, plus MRI-guided if abnormal MRI) will be offered. In men with phi < 35 (lower risk of prostate cancer), prostate biopsy (systematic plus MRI-guided) will be offered only if MRI is abnormal. |
||||||||
---|---|---|---|---|---|---|---|---|---|
Overall Status | Recruiting | ||||||||
Start Date | 2021-11-11 | ||||||||
Completion Date | 2023-12-31 | ||||||||
Primary Completion Date | 2023-09-30 | ||||||||
Study Type | Observational | ||||||||
Primary Outcome |
|
||||||||
Secondary Outcome |
|
||||||||
Enrollment | 159 |
Condition | |
---|---|
Eligibility |
Sampling Method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Ethnically Chinese Men ≥18 years of age - Clinical suspicion of prostate cancer and indicated for prostate biopsy - Serum Prostate-specific antigen (PSA) 4-10 ng/mL - Serum Prostate health index (phi) result available - Normal Digital rectal examination - Able to provide written informed consent Exclusion Criteria: - Past or current history of prostate cancer - On 5-alpha reductase inhibitor in the past 6 months (e.g. Finasteride, Dutasteride) - MRI prostate performed in past 5 years - Contraindicated to undergo MRI scan (e.g. pacemaker in-situ, claustrophobia, estimated glomerular filtration rate < 50ml/min in serum renal function test within 3 months) - Contraindicated for prostate biopsy (e.g. uncorrectable coagulopathy, active infection Gender: Male Gender Based: Yes Minimum Age: 18 Years Maximum Age: N/A Healthy Volunteers: No |
Overall Official |
|
||||||
---|---|---|---|---|---|---|---|
Overall Contact |
Last Name: Peter Ka-Fung CHIU, FRCS, PhD Phone: 35052625 Email: [email protected] |
||||||
Location |
|
Location Countries |
Hong Kong |
---|---|
Verification Date |
2022-06-01 |
Responsible Party |
Type: Principal Investigator Investigator Affiliation: Chinese University of Hong Kong Investigator Full Name: CHIU Ka Fung Peter Investigator Title: Associate Professor |
Has Expanded Access | No |
Condition Browse | |
Patient Data | No |
Study Design Info |
Observational Model: Cohort Time Perspective: Prospective |
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
NCT05384002RecruitingConditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent, Prostate Cancer Aggressiveness
-
NCT02381015CompletedConditions: Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
-
NCT05002465AvailableConditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
-
NCT03396874Active, not recruitingConditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
-
NCT03739684CompletedConditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
-
NCT04030338RecruitingConditions: Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
-
NCT04377152Approved for marketingConditions: Prostate Cancer, Prostate, Prostate Adenocarcinoma
-
NCT03763253RecruitingConditions: Prostate Cancer, Metastatic Prostate Cancer
-
NCT02297386CompletedConditions: Prostate Cancer, Localized Prostate Cancer
-
NCT03444844Active, not recruitingConditions: Prostate Cancer Recurrent, Prostate Cancer
Clinical Trials on
-
NCT03825016CompletedConditions: Pain
-
NCT03825003CompletedConditions: Hypermobility, Joint
-
NCT03824964Unknown statusConditions: Refractory B-Cell Lymphoma
-
NCT03824951Unknown statusConditions: Refractory B-Cell Lymphoma
-
NCT03824925CompletedConditions: Taste, Altered
-
NCT03824912CompletedConditions: Tinea Pedis
-
NCT03824899Unknown statusConditions: Locally Advanced Rectal Cancer
-
NCT03824873CompletedConditions: Blood Loss
-
NCT03824847Not yet recruitingConditions: Influenza, Human
-
NCT03824834RecruitingConditions: Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease